No profile data available.
Molecular Partners AG (MOLN) is a healthcare company in the medication development research industry, based in Schlieren, Switzerland, with about 134 full-time employees.
It reported revenue of 4.97 million CHF for fiscal year 2024, down 29.4% from fiscal year 2023, and net income of -54.04 million CHF. In Q2 2026 (the quarter ended June 30, 2026) revenue was 0 CHF. Its market capitalization was $147.48 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland.
Molecular Partners reported 4.97 million CHF in revenue for fiscal year 2024, down 29.4% from 7.04 million CHF in fiscal year 2023. In Q2 2026 revenue was 0 CHF.
$147.48 million as of October 9, 2026.
Listed companies of a similar size in the same industry (medication development research) include Absci Corporation (ABSI), Evotec SE (EVO), C4 Therapeutics, Inc. (CCCC), Insight Molecular Diagnostics Inc. (IMDX).